The Stars ratings are meant to ensure that every health plan is providing adequate services for members. For payers, meeting these ever-changing measures can be a challenge.
Meera Sundram, MSSW, LCSW, vice president of client program management at Change Healthcare presented “An Innovative Strategic Approach to Stars Improvement,” at Qualipalooza, the second annual RISE quality leadership summit in San Antonio, Texas, June 29 to 30. Managed Healthcare Executive (MHE) talked with Sundram in the days before the conference about her presentation and discussed how payers can use their existing data to target efforts for increasing Star ratings.
MHE: There are so many measures in the Star rating system. How can payers focus on which measures to address first?
Sundram: Take a look at national averages. If you’re trying to get from 3.5 to 4 stars but it’s a measure that a provider can only get a little movement because nationally no one is improving on, then it might not be worth spending time on. Look to areas where you can actually make improvement. Which are the most likely measures you can move, what are the best interventions, and what is the best way to implement and measure these interventions.
MHE: How do analytics help plans target Stars improvement?
Sundram: Analytics is a word everyone tosses around, but they are saying they want to look at new ways to look at available data and trends. Most take claims data and put it through an algorithm that allows them to see how members access care and what types of interventions might affect their pattern of use.
MHE: In your presentation you are discussing how to take this a step further. Tell us about advanced analytics and what that means?
Sundram: Advanced analytics could mean a lot. Mostly we are talking about ways to layer information to drive new interventions. When we talk about advanced analytics, I prefer to think about them a little more concretely. What I try to think about is how you take information and layer it. If you’re starting with claims data, how do you layer that with what else you know about a member (compliance, program participation, access, etc.).
MHE: Is this another way to use advanced analytics, by layering data?
Sundram: Layering starts with a Stars optimizing model that allows payers to plug in ‘what if’ scenarios and layer with historical performance measure by measure, then national averages. You can then layer in market specific performance-how competitors are performing-in that market.
I think sometimes what happens with Stars is there are 47 measures that are always moving around. Plans tend to kind of throw things at the wall to see what sticks. Without a full organization strategy to look at and analyze all that information, you’re only hoping to cross that line. Spend your time and money wisely in ways that you know can make a difference.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Doing More and Saving More with Primary in Home Care
September 1st 2021In this week’s episode of Tuning In to the C-Suite podcast, MHE Associate Editor Briana Contreras interviewed VillageMD’s Senior Medical Director of Village Medical at Home, Dr. Tom Cornwell. Dr. Cornwell discussed the main benefits of primary care at home, which includes the benefit of cost savings for patients, maintaining control of hospital readmissions and others. Dr. Cornwell also noted what has changed in the industry of at-home care and if there has been interest from payers like insurance companies and medicare in the service.
Listen
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More